Healthy Volunteers Clinical Trial
Official title:
Measuring Daily Grain Intake Study
| Verified date | March 2020 |
| Source | USDA Beltsville Human Nutrition Research Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The primary objective of this study is to identify markers of daily whole grain oat and whole grain wheat intake in humans.
| Status | Completed |
| Enrollment | 57 |
| Est. completion date | March 16, 2020 |
| Est. primary completion date | March 16, 2020 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 21 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Aged 21 - 75 years - non smokers Exclusion Criteria: - Body weight less than 110 lbs. - Have a body mass index below 19 or above 38 kg/m2 - Known (self-reported) allergy or adverse reaction to study foods - Women who have given birth during the previous 12 months or who are pregnant/lactating or who plan to become pregnant during the study - History of bariatric surgery or nutrient malabsorption disease (such as celiac disease), Crohn's disease, diabetes, or metabolic disorders that may interfere with the study - History of certain cancer diagnosis or treatment in the last 3 years - Smoking or use of tobacco products in the past 6 months - Suspected or known strictures, fistulas or physiological/mechanical GI obstruction - Use of certain medications or supplements (prescription or over-the-counter) that may interfere with the study objectives, including blood thinning medications - Unable or unwilling to give informed consent or communicate with study staff - Self-report of alcohol or substance abuse within the past 12 months and/or current treatment for these problems (long-term participation in Alcoholics Anonymous is not an exclusion) - Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol |
| Country | Name | City | State |
|---|---|---|---|
| United States | USDA-ARS Beltsville Human Nutrition Research Center | Beltsville | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| USDA Beltsville Human Nutrition Research Center | National Institute of Food and Agriculture |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 1 of Period 1 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 1 of Period 2 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 1 of Period 3 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 1 of Period 4 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 1 of Period 5 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 8 of Period 1 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 8 of Period 2 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 8 of Period 3 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 8 of Period 4 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 8 of Period 5 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 15 of Period 1 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 15 of Period 2 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 15 of Period 3 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 15 of Period 4 (period = 15 days) | |
| Primary | Identification of unknown blood biomarkers of grain intake | Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 15 of Period 5 (period = 15 days) | |
| Secondary | Identification of unknown urinary biomarkers of grain intake | Metabolomic analysis of urine samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined | Day 1, 8, and 15 of each of the 5 fifteen day diet periods | |
| Secondary | Characterization of fecal microbiota | Fecal samples will be analyzed for microbiota | Day 1, 8, and 15 of each of the 5 fifteen day diet periods | |
| Secondary | Blood Glucose | Fasting blood glucose will be measured in mg/dL | Day 1 and 15 of each of the 5 fifteen day diet periods | |
| Secondary | Blood Insulin | Fasting blood insulin will be measured in uIU/mL | Day 1 and 15 of each of the 5 fifteen day diet periods | |
| Secondary | Blood Triglycerides | Fasting blood triglycerides will be measured in mg/dL | Day 1 and 15 of each of the 5 fifteen day diet periods | |
| Secondary | Blood Non-Esterified Fatty Acids | Fasting blood non esterified fatty acids will be measured in mEQ/L | Day 1 and 15 of each of the 5 fifteen day diet periods |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |